The role of the LRRK2 gene in Parkinsonism

Molecular Neurodegeneration

Jin-Tai Yu¹  Lan Tan¹  Jie-Qiong Li¹ 

[1] Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao 266071, PR China

关键词: Pathogenic mechanism;    Clinical features;    Pathology;    Parkinsonism;    LRRK2;   

Others  :  1132672
DOI  :  10.1186/1750-1326-9-47

 received in 2014-08-15, accepted in 2014-10-21,  发布年份 2014

【 摘 要 】

Parkinson’s disease (PD), like many common age-related conditions, has been recognized to have a substantial genetic component. Multiple lines of evidence suggest that Leucine-rich repeat kinase 2 (LRRK2) is a crucial factor to understanding the etiology of PD. LRRK2 is a large, widely expressed, multi-domain and multifunctional protein. LRRK2 mutations are the major cause to inherited and sporadic PD. In this review, we discuss the pathology and clinical features which show diversity and variability of LRRK2-associated PD. In addition, we do a thorough literature review and provide theoretical data for gene counseling. Further, we present the evidence linking LRRK2 to various possible pathogenic mechanism of PD such as α-synuclein, tau, inflammatory response, oxidative stress, mitochondrial dysfunction, synaptic dysfunction as well as autophagy-lysosomal system. Based on the above work, we investigate activities both within GTPase and outside enzymatic regions in order to obtain a potential therapeutic approach to solve the LRRK2 problem.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kumari U, Tan EK: LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J 2009, 276:6455-6463.
• [2]Bardien S, Lesage S, Brice A, Carr J: Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 2011, 17:501-508.
• [3]Marin I: Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 2008, 67:41-50.
• [4]Gilsbach BK, Kortholt A: Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci 2014, 7:32.
• [5]Cardona F, Tormos-Perez M, Perez-Tur J: Structural and functional in silico analysis of LRRK2 missense substitutions. Mol Biol Rep 2014, 41(4):2529-2542.
• [6]Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA: LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci 2006, 29:286-293.
• [7]Skibinski G, Nakamura K, Cookson MR, Finkbeiner S: Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci 2014, 34:418-433.
• [8]Anand VS, Braithwaite SP: LRRK2 in Parkinson’s disease: biochemical functions. FEBS J 2009, 276:6428-6435.
• [9]Rideout HJ, Stefanis L: The Neurobiology of LRRK2 and its Role in the pathogenesis of Parkinson’s disease. Neurochem Res 2014, 39:576-592.
• [10]Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva G, Markova ED, Limborska SA, Ivanova-Smolenskaya IA: A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease in Russia. Eur J Neurol 2007, 14:413-417.
• [11]Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S: Mechanistic insight into the dominant mode of the Parkinson’s disease-associated G2019S LRRK2 mutation. Hum Mol Genet 2007, 16:2031-2039.
• [12]Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS: Type II kinase inhibitors show an unexpected inhibition mode against Parkinson’s disease-linked LRRK2 mutant G2019S. Biochemistry 2013, 52:1725-1736.
• [13]Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V: A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan. Neurogenetics 2006, 7:133-138.
• [14]Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, Smith WW: A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 2008, 105:2693-2698.
• [15]Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, Lim KL: Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009, 29:11257-11262.
• [16]Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Haque ME, Park DS: Leucine-rich repeat kinase 2 interacts with parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson’s disease. Hum Mol Genet 2009, 18:4390-4404.
• [17]Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B: LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009, 29:9210-9218.
• [18]Wolozin B, Saha S, Guillily M, Ferree A, Riley M: Investigating convergent actions of genes linked to familial Parkinson’s disease. Neurodegener Dis 2008, 5:182-185.
• [19]Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C: Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease. Nat Neurosci 2009, 12:826-828.
• [20]Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H: Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
• [21]Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, Shen J: R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009, 106:14622-14627.
• [22]Tong Y, Shen J: Genetic analysis of Parkinson’s disease-linked leucine-rich repeat kinase 2. Biochem Soc Trans 2012, 40:1042-1046.
• [23]Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis H, Plaitakis A, Ferreira JJ, Sampaio C, Bonifati V, Wu RM, Zabetian CP, Farrer MJ: Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 2009, 15:466-467.
• [24]Zhang Z, Burgunder JM, An X, Wu Y, Chen W, Zhang J, Wang Y, Xu Y, Gou Y, Yuan G, Mao X, Peng R: LRRK2 R1628P variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China. Mov Disord 2009, 24:1902-1905.
• [25]Pchelina SN, Ivanova ON, Emel’ianov AK, Iakimovskii AF: Clinical features of LRRK2-associated Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova 2011, 111:56-62.
• [26]Santpere G, Ferrer I: LRRK2 and neurodegeneration. Acta Neuropathol 2009, 117:227-246.
• [27]Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE: alpha-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013, 73:155-169.
• [28]Marti-Masso JF, Ruiz-Martinez J, Bolano MJ, Ruiz I, Gorostidi A, Moreno F, Ferrer I, Lopez de Munain A: Neuropathology of Parkinson’s disease with the R1441G mutation in LRRK2. Mov Disord 2009, 24:1998-2001.
• [29]Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S: Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 2009, 15:300-306.
• [30]Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A, Vilarino-Guell C, Thompson C, Szu Tu C, Gustavsson EK, Ben Sassi S, Hentati E, Zouari M, Farhat E, Nabli F, Hentati F, Farrer MJ: A comparative study of Parkinson’s disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging 2014, 35:1125-1131.
• [31]Shadrina MI, Illarioshkin SN, Bagyeva G, Bespalova EV, Zagorodskaia TB, Slominskii PA, Markova ED, Kliushnikov SA, Limborskaia SA, Ivanova-Smolenskaia IA: A PARK8 form of Parkinson’s disease: a mutational analysis of the LRRK2 gene in Russian population. Zh Nevrol Psikhiatr Im S S Korsakova 2007, 107:46-50.
• [32]Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Marti-Masso JF, Paisan-Ruiz C: The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson’s disease: clinical and demographic characteristics. Neurosci Lett 2013, 537:1-5.
• [33]Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW, North American Multiple System Atrophy Study Group: G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord 2007, 22:546-549.
• [34]Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP: Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008, 70:1456-1460.
• [35]Bichler Z, Lim HC, Zeng L, Tan EK: Non-motor and motor features in LRRK2 transgenic mice. PLoS One 2013, 8:e70249.
• [36]Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW: Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
• [37]Santos-Reboucas CB, Abdalla CB, Baldi FJ, Martins PA, Correa JC, Goncalves AP, Cunha MS, Borges MB, Pereira JS, Laks J, Pimentel MM: Co-occurrence of sporadic parkinsonism and late-onset Alzheimer’s disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test 2008, 12:471-473.
• [38]Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin VM: Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 2008, 70:521-527.
• [39]Shanker V, Groves M, Heiman G, Palmese C, Saunders-Pullman R, Ozelius L, Raymond D, Bressman S: Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Mov Disord 2011, 26:1875-1880.
• [40]Brockmann K, Groger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T: Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011, 26:2335-2342.
• [41]Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ: Analysis of 14 LRRK2 mutations in Parkinson’s plus syndromes and late-onset Parkinson’s disease. Mov Disord 2006, 21:997-1001.
• [42]Sellbach AN, Boyle RS, Silburn PA, Mellick GD: Parkinson’s disease and family history. Parkinsonism Relat Disord 2006, 12:399-409.
• [43]Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol 2008, 7:583-590.
• [44]Tao-Cheng JH: Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 2006, 141:1217-1224.
• [45]Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
• [46]Qing H, Wong W, McGeer EG, McGeer PL: Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 2009, 387:149-152.
• [47]Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24:197-211.
• [48]Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W, Maeir H, Poewe W, Lees AJ: Brain stem pathology in Parkinson’s disease: an evaluation of the Braak staging model. Mov Disord 2010, 25:2508-2515.
• [49]Kondo K, Obitsu S, Teshima R: alpha-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. Biol Pharm Bull 2011, 34:1078-1083.
• [50]Guerreiro PS, Huang Y, Gysbers A, Cheng D, Gai WP, Outeiro TF, Halliday GM: LRRK2 interactions with alpha-synuclein in Parkinson’s disease brains and in cell models. J Mol Med (Berl) 2013, 91:513-522.
• [51]Andreadis A: Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta 2005, 1739:91-103.
• [52]Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007, 8:663-672.
• [53]Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-Iqbal I: Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
• [54]Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
• [55]Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F: LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One 2012, 7:e30834.
• [56]Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, Taymans JM, Urban MK, Sancho RM, Ramirez MB, Biskup S, Baekelandt V, Cai H, Cookson MR, Berwick DC, Harvey K: A direct interaction between leucine-rich repeat kinase 2 and specific beta-tubulin isoforms regulates tubulin acetylation. J Biol Chem 2014, 289:895-908.
• [57]Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T, Maruyama H, Ichikawa T: Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3beta. FEBS J 2014, 281:3-13.
• [58]Caesar M, Zach S, Carlson CB, Brockmann K, Gasser T, Gillardon F: Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol Dis 2013, 54:280-288.
• [59]Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, H_glinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC: Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009, 16:297-309.
• [60]Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
• [61]Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O: Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 2004, 1:6. BioMed Central Full Text
• [62]McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG: Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 2006, 26:9365-9375.
• [63]Koprich JB, Reske-Nielsen C, Mithal P, Isacson O: Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 2008, 5:8. BioMed Central Full Text
• [64]Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG: Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011, 118:795-808.
• [65]Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK: LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 2010, 185:5577-5585.
• [66]Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB: LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 2012, 32:1602-1611.
• [67]Gillardon F, Schmid R, Draheim H: Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
• [68]Kim B, Yang MS, Choi D, Kim JH, Kim HS, Seol W, Choi S, Jou I, Kim EY, Joe EH: Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 2012, 7:e34693.
• [69]Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ: The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 2011, 12:1063-1070.
• [70]Shulman JM, De Jager PL, Feany MB: Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 2011, 6:193-222.
• [71]Yacoubian TA, Standaert DG: Targets for neuroprotection in Parkinson’s disease. Biochim Biophys Acta 2009, 1792:676-687.
• [72]Heo HY, Park JM, Kim CH, Han BS, Kim KS, Seol W: LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 2010, 316:649-656.
• [73]Pereira C, Miguel Martins L, Saraiva L: LRRK2, but not pathogenic mutants, protects against HO stress depending on mitochondrial function and endocytosis in a yeast model. Biochim Biophys Acta 2014, 1840(6):2025-2031.
• [74]Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, Tan EK: Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 2011, 32:1390-1397.
• [75]Angeles DC, Ho P, Chua LL, Wang C, Yap YW, Ng C, Zhou ZD, Lim KL, Wszolek ZK, Wang HY, Tan EK: Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum Mol Genet 2014, 23(12):3157-3165.
• [76]Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM: High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006, 38:515-517.
• [77]Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson NG: Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 2007, 104:1325-1330.
• [78]Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P: Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007, 16:1319-1326.
• [79]Cui J, Yu M, Niu J, Yue Z, Xu Z: Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system. Biosci Rep 2011, 31:429-437.
• [80]Niu J, Yu M, Wang C, Xu Z: Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 2012, 122:650-658.
• [81]Mortiboys H, Johansen KK, Aasly JO, Bandmann O: Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
• [82]Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG: LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. Neurobiol Dis 2010, 40:73-81.
• [83]Todde V, Veenhuis M, van der Klei IJ: Autophagy: principles and significance in health and disease. Biochim Biophys Acta 2009, 1792:3-13.
• [84]Liang CL, Wang TT, Luby-Phelps K, German DC: Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson’s disease. Exp Neurol 2007, 203:370-380.
• [85]Sanders LH, Laganiere J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B: LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis 2014, 62:381-386.
• [86]Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA: Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med 2012, 4:141ra190.
• [87]MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A: The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
• [88]Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT: Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 2008, 105:1048-1056.
• [89]Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N: Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007, 16:678-690.
• [90]Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R: LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009, 18:4022-4034.
• [91]Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL: Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006, 60:557-569.
• [92]Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, Meixner A, Sarioglu H, Vogt-Weisenhorn DM, Wurst W, Gloeckner CJ, Matteoli M, Sala C, Ueffing M: LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011, 31:2225-2237.
• [93]Garcia J, Erickson K, Raji C, Lopez O, Newman A, Rosano C, Kuller L: Physical activity is predictive of dementia but not mortality. Alzheimer’s and Dementia 2011, 7:S605.
• [94]Plowey ED, Chu CT: Synaptic dysfunction in genetic models of Parkinson’s disease: a role for autophagy? Neurobiol Dis 2011, 43:60-67.
• [95]Luzio JP, Pryor PR, Bright NA: Lysosomes: fusion and function. Nat Rev Mol Cell Biol 2007, 8:622-632.
• [96]Lubke T, Lobel P, Sleat DE: Proteomics of the lysosome. Biochim Biophys Acta 2009, 1793:625-635.
• [97]Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AH: Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010, 67:1464-1472.
• [98]Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M: Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci 2010, 30:12535-12544.
• [99]Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A: Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol Med 2012, 4:380-395.
• [100]Vila M, Bove J, Dehay B, Rodriguez-Muela N, Boya P: Lysosomal membrane permeabilization in Parkinson disease. Autophagy 2011, 7:98-100.
• [101]Friedman LG, Lachenmayer ML, Wang J, He L, Poulose SM, Komatsu M, Holstein GR, Yue Z: Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. J Neurosci 2012, 32:7585-7593.
• [102]Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, Savitt JM: Development and characterization of a new Parkinson’s disease model resulting from impaired autophagy. J Neurosci 2012, 32:16503-16509.
• [103]Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, Komatsu M, Abeliovich A: Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegeneration 2012, 7:48. BioMed Central Full Text
• [104]Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H: Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 2009, 29:13971-13980.
• [105]Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005, 25:1025-1040.
• [106]Bravo-San Pedro JM, Niso-Santano M, Gomez-Sanchez R, Pizarro-Estrella E, Aiastui-Pujana A, Gorostidi A, Climent V, Lopez de Maturana R, Sanchez-Pernaute R, Lopez de Munain A, Fuentes JM, González-Polo RA: The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci 2013, 70:121-136.
• [107]Bravo-San Pedro JM, Gomez-Sanchez R, Niso-Santano M, Pizarro-Estrella E, Aiastui-Pujana A, Gorostidi A, Climent V, Lopez de Maturana R, Sanchez-Pernaute R, Lopez de Munain A, Fuentes JM, González-Polo RA: The MAPK1/3 pathway is essential for the deregulation of autophagy observed in G2019S LRRK2 mutant fibroblasts. Autophagy 2012, 8:1537-1539.
• [108]Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Hino H, Kosaka K, Emson PC, Wada K, Dawson VL, Dawson TM, Arai H, Iseki E: Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol 2009, 68:994-1005.
• [109]Dodson MW, Zhang T, Jiang C, Chen S, Guo M: Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 2012, 21:1350-1363.
• [110]Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV, Shen J: Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegeneration 2012, 7:2. BioMed Central Full Text
• [111]Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MP, Plun-Favreau H, Giunti P, Tooze SA, Bandopadhyay R, Lewis PA: Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim Biophys Acta 1833, 2013:2900-2910.
• [112]Gomez-Suaga P, Hilfiker S: LRRK2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy. Autophagy 2012, 8:692-693.
• [113]Greenbaum L, Israeli-Korn SD, Cohen OS, Elincx-Benizri S, Yahalom G, Kozlova E, Strauss H, Molshatzki N, Inzelberg R, Spiegelmann R, Israel Z, Hassin-Baer S: The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson’s disease. Parkinsonism Relat Disord 2013, 19:1053-1056.
• [114]Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ: ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. a method to directly monitor the active conformation of LRRK2? J Neurosci Methods 2013, 214:62-68.
• [115]Burke RE: Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol Ther 2007, 114:261-277.
• [116]Cuny GD: Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des 2009, 15:3919-3939.
• [117]Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS: Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nat Chem Biol 2011, 7:203-205.
• [118]Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, Drewes G, Bantscheff M, Bard F, Dawson TM, Hopf C: Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons. ACS Chem Biol 2011, 6:1021-1028.
• [119]Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ: Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson’s disease. Neurotherapeutics 2013, 10:840-851.
• [120]Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG: Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 2013, 22:328-344.
• [121]Parkinson Study Group PI: Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007, 69:1480-1490.
• [122]Wang LH, Johnson EM Jr: Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2008, 71:462. author reply 462–463
• [123]Cookson MR: The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat Rev Neurosci 2010, 11:791-797.
• [124]Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG, Kalyanaraman B: Diapocynin prevents early Parkinson’s disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R(1)(4)(4)(1)G) transgenic mouse. Neurosci Lett 2013, 549:57-62.
• [125]Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT: The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 2009, 4:e8463.